Darrigues, Lauren
Pierga, Jean-Yves
Bernard-Tessier, Alice
Bièche, Ivan
Silveira, Amanda Bartolini
Michel, Marc
Loirat, Delphine
Cottu, Paul
Cabel, Luc
Dubot, Coraline
Geiss, Romain
Ricci, Francesco
Vincent-Salomon, Anne
Proudhon, Charlotte
Bidard, François-Clément http://orcid.org/0000-0001-5932-8949
Article History
Received: 25 October 2020
Accepted: 22 February 2021
First Online: 6 March 2021
Declarations
:
: Ethics approval and consent to participate are detailed in the “InternalRef removed” section. After providing their written informed consent, patients were prospectively included in the ethics committee-approved ALCINA study (NCT02866149). Eligibility criteria were patients aged > 18 years with ER+ HER2− MBC, treated at Institut Curie with endocrine therapy (AI or fulvestrant) and palbociclib.
: Not applicable.
: FC Bidard received research support and consulting fees from Pfizer, Novartis, and Lilly, unrelated to this study. The other authors have no disclosure.